

香港聯合交易所有限公司
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

Subject: **SZSE-Listed GALAXY BIOMEDICAL INVESTMENT (*ST) (SZSE Security Code: 000806)**

Enquiry: **Participant General Enquiry Hotline¹ (Tel : 2840 3626 E-mail : trd@hkex.com.hk)**

Exchange Participants (“EPs”) are requested to note that GALAXY BIOMEDICAL INVESTMENT (*ST) (SZSE Security Code: 000806) (“GALAXY BIOMEDICAL”) has issued an [announcement](#) (Chinese only) on Shenzhen Stock Exchange (“SZSE”) website. It states that the security will enter into a Delisting Arrangement Period (退市整理期) for 15 trading days (the “Delisting Arrangement Period”), i.e. the final period during which GALAXY BIOMEDICAL shares can be traded on SZSE before they are delisted from SZSE.

The Delisting Arrangement Period will commence from 13 June 2023 and trading of GALAXY BIOMEDICAL shares on SZSE will be resumed on the same date. The Delisting Arrangement Period is currently expected to end on 5 July 2023. Afterwards, GALAXY BIOMEDICAL shares will be delisted from SZSE. GALAXY BIOMEDICAL shares are Special China Connect Securities which are eligible for sell only in Northbound trading during the Delisting Arrangement Period.

For any EP who wishes to sell any GALAXY BIOMEDICAL shares through the use of the China Connect Service, it may only be able to do so on or before the end of the Delisting Arrangement Period. Upon completion of the delisting from SZSE, GALAXY BIOMEDICAL shares will be removed from the list of Special China Connect Securities and EPs will no longer be allowed to input any buy or sell order in respect of GALAXY BIOMEDICAL shares through the use of the China Connect Service.

EPs should also note that Hong Kong Securities Clearing Company Limited (“HKSCC”) will cease to render services in respect of the GALAXY BIOMEDICAL shares upon their delisting from SZSE. Please refer to the relevant circular(s) issued by HKSCC for details.

¹All calls to and from the Participant General Enquiry Hotline may be recorded. HKEX Privacy Policy Statement is available [here](#).

EPs are urged to consider the potential liquidity risk and other limitations as well as restrictions on holding GALAXY BIOMEDICAL shares after the end of the Delisting Arrangement Period and promptly take all necessary actions where appropriate. EPs are reminded to refer to announcement(s) available on SZSE website for details on the delisting of GALAXY BIOMEDICAL from SZSE and any other subsequent updates.

Olivia Mak
Senior Vice President
Trading Department
Operations Division